Intrexon Organizes Around New Synthetic Biology Markets
5/9/2013
Nine Collaborations Underway, Company Aligns to Accelerate Business Development in Health, Food, Energy and Environment
Germantown, Maryland, May 9, 2013 – Intrexon Corporation, a leader in synthetic biology that is helping companies design and develop products incorporating its Better DNA™, today announced it has aligned its industry markets to focus on four key sectors: Health, Food, Energy and Environment.
Intrexon currently has nine collaborations in Health and Food to create products embodying engineered bio-based solutions. The goal of the new...
Soligenix and Intrexon Pursue Melioidosis Therapy Through Worldwide Exclusive Collaboration
5/1/2013
Soligenix to Expand Biodefense and Infectious Disease Product Pipeline
Princeton, NJ and Germantown, MD – May 1, 2013 – Soligenix, Inc. (OTCQB: SNGX), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today it will jointly develop a treatment for Melioidosis through a worldwide exclusive collaboration with Intrexon, a synthetic biology company that utilizes its proprietary technologies to provide control over cellular function.
...
Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
5/1/2013
Germantown, Maryland, May 1, 2013 – Intrexon Corporation, a next generation synthetic biology company, today announced that it has closed a Series F preferred investment round of $150 million, bringing the company’s total capital raised to $509 million. New investors accounted for the majority of the round, with current investors, including affiliates of Randal J. Kirk, Intrexon’s Chairman and CEO, and Third Security, LLC, taking the balance of the round.
The funding will be used to provide working capital for the establishment of additional exclusive channel...
AmpliPhi Establishes Collaboration with Intrexon
4/16/2013
Combined Expertise to Create New Generation of Bacteriophage-Based Therapeutics For Antibiotic Resistant Infections
Richmond, VA, and Germantown, MD, April 16, 2013 – AmpliPhi BioSciences Corp. (OTC: APHB), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, and Intrexon Corporation, a synthetic biology company that utilizes its proprietary technologies to provide control over cellular function, today announced the formation of an exclusive channel collaboration (“ECC”) to develop new bacteriophage-based...
ZIOPHARM Presents Preclinical Data Supporting DNA-based IL-12 Therapy for Breast Cancer
4/9/2013
Immunotherapeutic Strategy Results Presented at AACR 2013 Annual Meeting
NEW YORK, NY – April 9, 2013 – ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today the presentation of results from a study in a breast cancer murine model demonstrating the anti-tumor effects and tolerability of Ad-RTS-mIL-12, a viral vector DNA-based therapeutic for the controlled, local expression of IL-12, an important protein for enhancing antitumor immunity. The data were...
ZIOPHARM Oncology Initiates Phase 2 Study of Ad-RTS IL-12 and Palifosfamide Combination for Treatment of Advanced Breast Cancer
3/11/2013
NEW YORK, NY – March 11, 2013 – ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the initiation of a randomized, open label Phase 2 clinical study of Ad-RTS IL-12 in combination with palifosfamide to treat patients with non-resectable recurrent or metastatic breast cancer.
The two-part, multi-center U.S. study will enroll up to 68 patients with non-resectable, recurrent or metastatic breast cancer who have visible lesions or lesions accessible by injection. The study is...
Intrexon and AquaBounty to Collaborate on Leveraging Synthetic Biology to Increase Productivity Across the Aquaculture Arena
2/15/2013
-Exclusive Channel Collaboration Driven by Need to Meet Growing World Food Demand
-Intrexon Proposes to invest up to $6.0 million in AquaBounty
Germantown, MD and Maynard, MA – February 15, 2013 - Intrexon Corporation, a synthetic biology company that utilizes its proprietary technologies to provide control over cellular function, and AquaBounty Technologies, Inc. (AIM:ABTX.L), a biotechnology company focused on enhancing the productivity in aquaculture, today announced the formation of an exclusive channel collaboration (ECC) to enhance productivity in aquaculture and...
Intrexon Completes Mandatory Tender Offer for AquaBounty Technologies Shares
1/7/2013
Blacksburg, Virginia – January 7, 2013 - Intrexon Corporation, a synthetic biology company that utilizes its proprietary technologies to provide control over cellular function, today announced that it has elected not to extend the mandatory tender offer that it was required to make for the outstanding shares not already owned by it in AquaBounty Technologies, Inc. (AIM:ABTX), a biotechnology company focused on enhancing the productivity in aquaculture. As a result, the tender offer expired at 1:00 p.m. London time on January 4, 2013. The offer satisfied a requirement of...
Sanford-Burnham Medical Research Institute and Intrexon Corporation Establish Collaboration to Accelerate Stem Cell Research
1/3/2013
Combines Sanford-Burnham’s renowned scientific team and Intrexon’s proprietary discovery platforms to accelerate human induced pluripotent stem cell (iPSC) research
LA JOLLA, Calif., January 3, 2013 – Sanford-Burnham Medical Research Institute, a nonprofit research institution and one of the largest iPSC generators in the world, and Intrexon Corporation, a leading synthetic biology company, today announced a new collaboration to accelerate stem cell research. Under the agreement, Sanford-Burnham will gain access to sophisticated proprietary cellular selection and...
Synthetic Biologics and Intrexon Corporation Initiate Development of Monoclonal Antibodies for Whooping Cough (Pertussis)
12/20/2012
-- The University of Texas at Austin to Join in Pertussis Research Efforts --
Rockville, MD, and San Francisco, CA, December 20, 2012 – Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, and Intrexon Corporation, a leading synthetic biology company that utilizes its proprietary technologies to provide control over cellular function, announced today that they have initiated development of a monoclonal antibody (mAb) therapy for the treatment of pertussis, more commonly known as whooping cough....
ZIOPHARM Oncology Presents Systemic, DNA/Cell Plasmid Therapy Showing Long-Term Persistence and Anti-Tumor Effects at EORTC-NCI-AACR Meeting
11/7/2012
NEW YORK, NY – November 7, 2012 – ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today results from a preclinical study demonstrating the long-term persistence and anti-tumor effects of a new synthetic biology approach (DNA/cell plasmid) to controlled protein production in vivo. This embedded controlled bioreactor study was presented at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, taking place November 6-9 in Dublin, Ireland, and...
Intrexon to Acquire 48% Stake in AquaBounty Technologies
11/1/2012
- Utilizing Biotechnology to Improve Productivity in Aquaculture
Blacksburg, Virginia – October 31, 2012 - Intrexon Corporation, a synthetic biology company that utilizes its proprietary technologies to provide control over cellular function, today announced that it has entered into a definitive purchase agreement to acquire an approximately 48% interest in AquaBounty Technologies, Inc. (AIM:ABTX), a biotechnology company focused on enhancing the productivity in aquaculture, from existing shareholders. Pursuant to the purchase agreement, Intrexon will purchase 48,631,444...